Evaluation of Endocrine Late Complications in Childhood Acute Lymphoblastic Leukemia Survivors: A Report of a Single-Center Experience and Review of the Literature

Cengiz Bayram¹, Neşe Yaralı¹, Ali Fettah¹, Fatma Demirel², Betül Tavil³, Abdurrahman Kara¹, Bahattin Tunç¹

¹Ankara Children’s Hematology and Oncology Hospital, Clinic of Pediatric Hematology, Ankara, Turkey
²Private Doctor

Abstract

Objective: Improvement in long-term survival in patients with acute lymphoblastic leukemia (ALL) in childhood has led to the need for monitoring of treatment-related morbidity and mortality. In the current study, we aimed to evaluate endocrine side effects of treatment in ALL survivors who were in remission for at least 2 years.

Materials and Methods: Sixty patients diagnosed with ALL, who were in remission for at least 2 years, were cross-sectionally evaluated for long-term endocrine complications.

Results: The median age of the patients at the time of diagnosis, at the time of chemotherapy completion, and at the time of the study was 5 years (minimum-maximum: 1.7-13), 8 years (minimum-maximum: 4.25-16), and 11.7 years (minimum-maximum: 7-22), respectively, and median follow-up time was 4 years (minimum-maximum: 2-10.1). At least one complication was observed in 81.6% of patients. Vitamin D insufficiency/deficiency (46.6%), overweight/obesity (33.3%), and dyslipidemia (23.3%) were the three most frequent endocrine complications. Other complications seen in our patients were hyperparathyroidism secondary to vitamin D deficiency (15%), insulin resistance (11.7%), hypertension (8.3%), short stature (6.7%), thyroid function abnormality (5%), precocious puberty (3.3%), and decreased bone mineral density (1.7%). There were no statistically significant correlations between endocrine complications and age, sex, and radiotherapy, except vitamin D insufficiency/deficiency, which was significantly more frequent in pubertal ALL survivors compared to prepubertal ALL survivors (57.5% and 25%, respectively, p=0.011).

Conclusion: A high frequency of endocrine complications was observed in the current study. The high frequency of late effects necessitates long-term surveillance of this population to better understand the incidence of late-occurring events and the defining of high-risk features that can facilitate developing intervention strategies for early detection and prevention.

Keywords: Acute lymphoblastic leukemia, Endocrine, Late effects, Children

Amaç: Akut lenfoblastik lösemili (ALL) hastalardaki sağ kalmının artması, tedavi sonrası ortaya çıkan morbidity ve mortalite problemlerinin takip edilmesi ihtiyacını beraberinde getirmiştir. Çalışmamızda, en az iki yıldır remisyonda olan ALL’li hastalarda, tedavi sonrası ortaya çıkabilecek endokrin komplikasyonların değerlendirilmesi amaçlanmıştır.

Gereç ve Yöntemler: ALL tanısı ile tedavi almış ve tedavisi üzerinden 60 hasta endokrin geç yan etkilerin değerlendirildiği seen 81,6’nda en az bir endokrin komplikasyon görüntüldü. D vitamini eksikliği/yetersizliği (%46,6), obezite/fazla kiloluluk (%33,3) ve dislipidemi (%23,3) en sık gelişen üç komplikasyon olarak tespit edildi. D vitamini eksikliğini sekenin hiperparatiroidi (%15), insulin direnci (%11,7), hipertansiyon (%8,3), boy kısalığı (%6,7), tiroid fonksiyon bozukluğu (%6), puberte prekoks (%3,3) ve azalmış kemik mineral yoğunluğu (%1,7) gelişen diğer endokrin komplikasyonlardı. Hastalarda gelişen endokrin komplikasyonların arasında cinsiyet, yaş, radyoterapi bakımından farklılık saptanmaz iken, D vitamini yetersizliği/eksikliği saptanan hasta sayısını pompalı gruba, prepubertal grubu göre anlamlı derecede fazladı (%57,5 ve %25, sırasıyla, p=0,011).

Sonuç: Çalışmamızda yüksek oranında endokrin komplikasyon saptandı. Bu komplikasyonlar, geç yan etkilerin ortaya çıkışına neden olabilecek yüksek risk özellikleri ve skilini tanımlayabilir, erken tanı ve önleyici stratejileri gelişirmek açısından hastaların uzun dönem izlenmelerini gerektirir.

Anahtar Sözcükler: Akut lenfoblastik lösemi, Endokrin, Geç yan etkiler, Çocuk

Address for Correspondence/Yazışma Adresi: Cengiz BAYRAM, M.D., Ankara Children’s Hematology and Oncology Hospital, Clinic of Pediatric Hematology, Ankara, Turkey
Phone: +90 505 839 60 92
E-mail: cengizbayram2013@gmail.com

Accepted/Kabul tarihi: November 18, 2015

DOI: 10.4274/tjh.2015.0332
Turk J Hematol 2017;34:40-45
Introduction

Despite the increase in the prevalence of childhood malignancies, the 5-year survival rate for acute lymphoblastic leukemia (ALL) in childhood has approached 90% as a result of advances in chemotherapy and supportive care. This increase in survival has increased the importance of long-term treatment-related morbidity and mortality [1]. One of the consequences of cancer or its therapy is that many long-term survivors of childhood cancer are at an increased risk of developing chronic physical or psychosocial problem [2]. It is estimated that about two-thirds of cancer survivors will experience at least one late adverse effect and more than 40% may have a severe, disabling, or life-threatening condition or may die 30 years after the cancer is diagnosed [3]. There have been numerous chemotherapy agents used for the treatment of ALL; however, a few of them have been implicated as causing late effects, including anthracyclines (e.g., doxorubicin, daunorubicin), oxazaphosphorine alkylating agents (e.g., cyclophosphamide), corticosteroids (e.g., prednisone, dexamethasone), and high-dose methotrexate [2]. The adverse effects of prophylactic cranial irradiation, including acute neurotoxicity, neurocognitive deficits, endocrinopathies, secondary malignant disease, and excess late mortality, have led to its reduction or elimination from treatment protocols for ALL [4,5,6].

Endocrine complications during therapy for ALL include bone demineralization, disordered growth, adrenocortical insufficiency, diabetes mellitus, the syndrome of inappropriate secretion of antidiuretic hormone, and changes in thyroid hormone concentration, whereas late complications, those that occur after completion of all radiation and chemotherapy, include bone demineralization, short stature, growth hormone deficiency, obesity, hypothyroidism, gonadal dysfunction, and infertility [7]. The present study aimed to evaluate long-term endocrine complications in ALL survivors that were in remission for at least 2 years.

Materials and Methods

Sixty patients diagnosed with ALL between January 2003 and February 2009 at the Pediatric Hematology Clinic of Ankara Children’s Hematology and Oncology Education and Research Hospital, who were in remission for at least 2 years, were included in the study and were evaluated cross-sectionally. All patients with ALL were treated according to the St. Jude Total-XIII protocol [8] and received 12 or 18 cGy cranial radiotherapy (CRT) as a part of prophylaxis or treatment as appropriate.

Pubertal status was assessed at the time of the study using Tanner staging and patients were divided into two groups as pubertal or prepubertal. Body weight and height were measured and evaluated according to Turkish children’s growth data [9]. Body mass index (BMI) was calculated as weight in kilograms divided by the square of the height in meters. Overweight was defined as BMI for age and sex between the 85th and 95th percentiles, and BMI for age and sex higher than the 95th percentile was defined as obesity.

Hormonal analysis was carried out by the chemiluminescence method using a BIO-DPC hormone autoanalyzer with commercial kits, and a Roche/Hitachi Modular P Chemistry Analyzer was used for biochemical analysis. Serum lipid profiles, including cholesterol, triglyceride, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and blood glucose, were obtained after at least 8 h of fasting. Dyslipidemia was defined as cholesterol of >200 mg/dL, or triglyceride of >150 mg/dL, or LDL-C of >130 mg/dL, or HDL-C of <40 [10]. The homeostasis model assessment (HOMA) score was calculated using the following formula: [fasting glucose (mmol/L) × insulin (mmol/L)]/22.5. A HOMA score above 2.5 for prepubertal patients and above 3.2 for pubertal patients was accepted as evidence of insulin resistance [11,12]. Metabolic syndrome was defined as the presence of three or more of the following: 1) hypertension, 2) glucose intolerance, 3) hypertriglyceridemia, 4) decreased HDL level, and 5) central abdominal obesity [13]. Low free thyroxine (T4) and thyroid-stimulating hormone (TSH) level of >10 µU/mL with clinical symptoms were defined as hypothyroidism, and normal free T4 level and TSH level between 5 and 10 µU/mL without clinical symptoms were defined as subclinical (compensated) hypothyroidism [14]. Parathyroid hormone (PTH) values between 6 and 65 pg/mL were accepted as normal. High PTH levels with vitamin D deficiency were diagnosed as “secondary hyperparathyroidism”. Patients having hypocalcemia, hyperphosphatemia, and decreased PTH levels were diagnosed with “primary hypoparathyroidism”. Serum adrenocorticotrophic hormone (ACTH) and cortisol levels were simultaneously measured at 09:00 hours. ACTH levels between 7 and 28 pg/mL for prepubertal children and between 2 and 49 pg/mL for postpubertal children were accepted as normal. Cortisol levels between 8 and 22 µg/dL were accepted as normal, whereas <8 µg/dL was accepted as adrenal insufficiency [15]. Serum 25-OH-vitamin D levels less than 15 ng/mL were diagnosed as a sign of vitamin D deficiency (normal: 20–100 ng/mL) and values between 15 and 20 ng/mL were considered as vitamin D insufficiency [16]. Bone mineral density (BMD) was measured by using dual energy X-ray absorptiometry from the L1-L4 lumbar vertebrae and was assessed according to bone ages appropriately for Turkish children’s data [17]. Age- and sex-adjusted Z-scores of less than -2 were considered as evidence of decreased BMD.

The study was approved by the hospital ethics committee, and informed consent was obtained from the parents of all participating subjects.
Continuous variables are expressed as median (minimum-maximum) and categorical variables as number (percentage). The clinical parameters and laboratory values of the patients were evaluated using the chi-square method and Student’s t-test, as appropriate. All statistical tests were two-sided and p<0.05 was considered statistically significant. Statistical analysis was performed using SPSS 18.0 for Windows (SPSS Inc., Chicago, IL, USA).

Results

Of the 60 ALL survivors, 31 (51.7%) were male and 29 (48.3%) were female. Fifty-five patients (91.7%) were diagnosed with pre-B-cell ALL and five (8.3%) were diagnosed with T-cell ALL. Overall, 21 patients (35%) received 12 or 18 cGy CRT as a part of prophylaxis or treatment as appropriate. The median age of the patients at the time of diagnosis, at the time of chemotherapy completion, and at the time of the study was 5 years (minimum-maximum: 1.7-13), 8 years (minimum-maximum: 4.25-16), and 11.7 years (minimum-maximum: 7-22), respectively, and median follow-up time was 4 years (minimum-maximum: 2-10.1). Demographic data of patients are summarized in Table 1.

One or more adverse events occurred in 81.6% of the 60 ALL survivors; 25 patients (41.6%) had one endocrine complication, 17 patients (28.3%) had two endocrine complications, 5 patients (8.3%) had three endocrine complications, and 2 patients (3.3%) had four endocrine complications. Vitamin D insufficiency/deficiency (46.6%), overweight/obesity (33.3%), and dyslipidemia (23.3%) were the three most frequent endocrine complications, followed by hyperparathyroidism secondary to vitamin D deficiency (15%), insulin resistance (11.7%), hypertension (8.3%), short stature (6.7%), thyroid function abnormality (5%), precocious puberty (3.3%), and decreased BMD (1.7%). There were no patients diagnosed with adrenal insufficiency, as serum ACTH and cortisol levels were within the normal ranges for all patients (Table 2).

There were four patients (6.6%) with three components of metabolic syndrome, seven patients (11.6%) with two components of metabolic syndrome, and 18 patients (30%) with one component of metabolic syndrome. Of the seven patients with insulin resistance, five had overweight or obesity, and two patients had normal BMI.

In the present study, long-term endocrine complications in 60 ALL survivors were also assessed with respect to age (<5 years versus >5 years), sex (male versus female), pubertal status (pubertal versus prepubertal), and either CRT administered or not. No significant differences were observed with respect to age, sex, and cranial radiotherapy, whereas vitamin D insufficiency/deficiency was significantly more frequent in pubertal ALL survivors (57.5%) as compared to prepubertal ALL survivors (25%) (Table 3).

Discussion

Despite the increase in the prevalence of childhood cancer, with a 0.6% increase in incidence rates for all childhood cancers noted during 1975-2002, a reduction in the mortality rate has been achieved through multimodal chemotherapy and enhanced supportive care [18]. However, as a consequence of treatment-related complications, recurrence of primary cancer, and subsequent malignancies, approximately two-thirds of this population is reported to have one or more late adverse effects [18,19,20,21]. In concordance with previous reports, one or more adverse events occurred in 81.6% of the present study’s ALL survivors. Vitamin D insufficiency/deficiency (46.6%) was the most frequent endocrine complication in the current study. ALL survivors are at increased risk of developing late adverse effects, including endocrine complications.

| Table 1. Patient characteristics. |
|----------------------------------|
| **Sex, n (%)**                   |
| Male                             | 31 (51.7) |
| Female                           | 29 (48.3) |
| **Leukemia type, n (%)**         |
| B-cell                           | 55 (91.7) |
| T-cell                           | 5 (8.3)   |
| **Median age, years (minimum-maximum)** |
| At the time of diagnosis         | 5 (1.7-13) |
| At the time of chemotherapy completion | 8 (4.25-16) |
| At the time of the study         | 11.7 (7-22) |
| **Median follow-up time, years (range)** |
| Chemotherapy protocol, n (%)     |
| St. Jude Total-XIIIA protocol    | 60 (100)  |
| Cranial radiotherapy, n (%)      |
| CRT+                             | 21 (35)   |
| CRT-                             | 39 (65)   |
| CRT+: Received cranial radiotherapy; CRT-: did not receive cranial radiotherapy.

| Table 2. Endocrine complications. |
|----------------------------------|
| **Endocrine complications, n (%)** |
| Vitamin D insufficiency/deficiency | 28 (46.6) |
| Overweight/obesity               | 20 (33.3) |
| Dyslipidemia                     | 14 (23.3) |
| Hyperparathyroidism secondary to vitamin D deficiency | 9 (15) |
| Insulin resistance               | 7 (11.7)  |
| Hypertension                     | 5 (8.3)   |
| Short stature                    | 4 (6.6)   |
| Thyroid function abnormality     | 3 (5)     |
| Precocious puberty               | 2 (3.3)   |
| Decreased bone mineral density   | 1 (1.7)   |

Bayram C, et al: Endocrine Late Complications in Childhood Leukemia Survivors Turk J Hematol 2017;34:40-45
BMD deficits compared to the general population, associated with their treatment, including high cumulative doses of steroids/methotrexate and radiation therapy. Because vitamin D has a positive influence on calcium balance for building bone and attaining peak bone mass, vitamin D deficiency or insufficiency can contribute to BMD deficit [22]. The prevalence of 25-hydroxyvitamin D (25-OH-D) insufficiency is reported to be 14-49% in the general population and was reported to be between 33.5% and 40% in healthy Turkish children and adolescents in two recent studies [23,24,25,26]. In a recent study of 484 childhood cancer survivors, 17.6% of whom had leukemia, Choudhary et al. reported a prevalence of 29% of 25-OH-D insufficiency, and the risk factors for 25-OH-D insufficiency were race, pubertal status, and seasonality [27]. The prevalence of 25-OH-D deficiency or insufficiency was 46.6% in our study, which was higher than in the latter study and two recent studies from Turkey but similar to what has been described in the general population. Pubertal status was the only significant risk factor in the present study, while 23 of 28 patients (82.1%) with 25-OH-D deficiency or insufficiency were pubertal ALL survivors. Forty percent of bone mass is obtained during puberty, and by the end of puberty, 90% of total adult bone mass has already been acquired in the normal population [22]. In this regard, in addition to chemotherapy agents and radiation therapy, 25-OH-D deficiency or insufficiency can additionally contribute to failure to recover to a normal BMD after completion of therapy, and thus surveillance and intervention strategies should also include assessment of 25-OH-D levels during puberty.

Overweight or obesity has been identified as a potential late adverse effect of therapy in childhood ALL survivors [2,3]. The largest study evaluating the risk of being overweight in ALL survivors was conducted by the Childhood Survivor Cancer Study. That study showed that survivors who received greater than 20 Gy CRT were significantly more likely than their siblings to be overweight, and female survivors treated before the age of 4 years were also more likely to be overweight in comparison with siblings [28]. Studies about the risk of being overweight or obese in ALL survivors have conflicting results. In a study of 618 ALL survivors, reported by Dalton et al., they found that children treated before the age of 13 years had a significant decrease in their height z-scores and an increase in their BMI z-scores, regardless of cranial radiation therapy [29]. Razzouk et al. observed that young age (<6 years) and overweight/obesity at diagnosis were the best predictors of obesity at adult height in a study of 456 childhood ALL and lymphoma survivors, 431 of whom had ALL [30]. That study further concluded that BMI weight category at diagnosis, rather than type of CNS treatment received, predicted adult weight in long-term survivors of childhood hematologic malignancies. Zhang et al. reported that weight status at diagnosis and BMI z-score at diagnosis were both significant predictors for being overweight/obese at the end of treatment in pediatric ALL survivors [31]. They found that patients who were overweight/obese at diagnosis were 11.9 times more likely to be overweight/obese at the end of treatment than those who were underweight or had healthy weight at diagnosis. Moreover, sex, receiving CRT, and age at diagnosis were not significant predictors of BMI z-score in survivors of pediatric ALL during or after treatment. In the present study, we also did not observe any significant correlation between the risk of being overweight or obese and age at diagnosis, CRT, and sex. Additionally, Asner et al. showed an association between abnormal maternal BMI and overweight/obesity in long-term survivors of childhood ALL, except for overweight/obesity at diagnosis, while age at diagnosis, sex, cumulative dose of steroids, and paternal BMI showed no association [32]. In a previous study of 33 ALL survivors, 25 of whom were female, it was found that 56% of female survivors were obese and 59% of them had an obese mother [33]. Considering the risk of long-term excessive weight gain in childhood ALL survivors including overweight/obesity at diagnosis and abnormal maternal BMI, rather than CRT, corticosteroids, age at diagnosis, and sex, the patient's familial and genetic characteristics are likely to be risk factors leading to overweight/obesity for this population.

ALL survivors are reported to have a 4-fold excess risk of mortality secondary to cardiovascular events compared to the

| Endocrine complications, n (%) | Total (n=60) | Pubertal (n=40) | Prepubertal (n=20) | p    |
|-------------------------------|-------------|----------------|-------------------|------|
| Vitamin D insufficiency/deficiency | 28 (46.6)  | 23 (57.5)  | 5 (25)            | 0.011* |
| Overweight/obesity            | 20 (33.3)  | 12 (30)     | 8 (40)            | 0.439 |
| Dyslipidemia                  | 14 (23.3)  | 10 (25)     | 4 (20)            | 0.666 |
| Hyperparathyroidism secondary to vitamin D deficiency | 9 (15) | 7 (17.9) | 2 (10) | 0.443 |
| Insulin resistance            | 7 (11.7)   | 5 (12.5)    | 2 (10)            | 0.591 |
| Hypertension                  | 5 (8.3)    | 4 (10)      | 1 (5)             | 0.509 |
| Short stature                 | 4 (6.6)    | 2 (5)       | 2 (10)            | 0.464 |
| Thyroid function abnormality  | 1 (1.7)    | 2 (5)       | 1 (5)             | 1.000 |

*Significant.
development of intervention strategies for early detection and important to better understand the incidence of late-occurring general population, long-term surveillance of this population is as a consequence of ALL or its therapy as compared to the context, considering the high prevalence of late adverse effects of childhood ALL survivors. In this cohort [34,35]. Reduction or elimination of CRT in treatment of childhood ALL in recent protocols is another reason for favorable outcome in the context of central endocrinopathy development [4,5,6]. In the present study, there were no patients diagnosed with adrenal insufficiency, and the frequency of patients with hypothyroidism and subclinical hypothyroidism (compensated) was 1.7% and 3.3%, respectively. Only two of 60 ALL survivors developed precocious puberty; both were girls and one received CRT.

Conclusion

In conclusion, a high frequency of endocrine long-term adverse events occurred in the current study. In achieving >90% of 5-year survival rates for children with ALL diagnosed at 14 years of age or younger, there has been an increase in the number of children and adolescents cured of ALL. In this context, considering the high prevalence of late adverse effects as a consequence of ALL or its therapy as compared to the general population, long-term surveillance of this population is important to better understand the incidence of late-occurring events and define high-risk features that can facilitate the development of intervention strategies for early detection and prevention, which can lead to an improvement of care and quality of life for this growing population.

Ethics

Ethics Committee Approval: The research has been approved by Ankara Children’s Hematology and Oncology Hospital’s ethics committee (approval number 2013-051) and informed consent was obtained from the parents of the patients. The manuscript has been seen and approved by all of the authors.

Author Contributions

Concept: Cengiz Bayram, Neşe Yaralı, Betül Tavil; Design: Cengiz Bayram, Neşe Yaralı, Betül Tavil, Fatma Demirel; Data Collection or Processing: Cengiz Bayram, Neşe Yaralı, Ali Fettah, Fatma Demirel; Analysis or Interpretation: Cengiz Bayram, Neşe Yaralı, Ali Fettah, Fatma Demirel; Literature Search: Cengiz Bayram, Neşe Yaralı, Ali Fettah, Fatma Demirel, Betül Tavil, Abdurrahman Kara, Bahattin Tunç; Writing: Cengiz Bayram, Neşe Yaralı, Ali Fettah, Fatma Demirel, Betül Tavil, Abdurrahman Kara, Bahattin Tunç.

Conflict of Interest: The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.

References

1. Ness KK, Armenian SH, Kadan-Lottick N, Gurney JG. Adverse effects of treatment in childhood acute lymphoblastic leukemia: general overview and implications for long-term cardiac health. Expert Rev Hematol 2011;4:185–197.
2. Nathan PC, Wasilewski–Masker K, Janzen LA. Long-term outcomes in survivors of childhood acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2009;23:1065–1082.
3. Shankar SM, Marina N, Hudson MM, Hodgson DC, Adams MJ, Lander W, Bhatia S, Meeske K, Chen MH, Kinahan KE, Steinberger J, Rosenthal D; Cardiovascular Disease Task Force of the Children’s Oncology Group. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children’s Oncology Group. Pediatrics 2008;121:e387–396.
4. Inaba H, Greaves M, Mulilghan CG. Acute lymphoblastic leukaemia. Lancet 2013;381:1943–1955.
5. Veerman AJ, Kamps WA, van den Berg H, van den Berg E, Bökkerink JP, Bruin MC, van den Heuvel–Elbrink MM, Korijn CM, Korthof ET, van der Pal K, Stijnen T, van Weel Shipman MH, van Weerden JV, van Wering ER, van der Does-van den Berg A; Dutch Childhood Oncology Group. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997–2004). Lancet Oncol 2009;10:957–966.
6. Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC, Ribeiro RC, Rubnitz JE, Raimondi SC, Onciu M, Coustans–Smith E, Kun LE, Jeha S, Cheng C, Howard SC, Simmons V, Bayles A, Metzger ML, Boyett JM, Leung W, Handgretinger R, Downing JR, Evans WE, Reiling MV. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009;360:2730–2741.
7. Howard SC, Pui CH. Endocrine complications in pediatric patients with acute lymphoblastic leukemia. Blood Rev 2002;16:225–243.
20. Geenen MM, Boyett JM, Rivera GK, Hancock ML, Sandlund JT, Ribeiro RC, Rubnitz JE, Behm FG, Raimondi SC, Gajjar A, Razzouk B, Campana D, Kun LE, Reiling MV, Evans WE. Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia 2000;14:2286-2294.

9. Neyzi O, Furman A, Bundak R, Goun P, Darendeliler F, Bas F. Growth references for Turkish children aged 6 to 18 years. Acta Paediatr 2006;95:1635-1641.

8. Pui CH, Boyett JM, Rivera GK, Hancock ML, Sandlund JT, Ribeiro RC, Rubnitz JE, Behm FG, Raimondi SC, Gajjar A, Razzouk B, Campana D, Kun LE, Reiling MV, Evans WE. Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia 2000;14:2286-2294.

7. Greenspan FS. Greenspan's Basic & Clinical Endocrinology, 9th ed. New York, McGraw-Hill Medical, 2011.

6. Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M; Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics 2008;122:398-417.

5. Akman AO, Tumer L, Hasanoglu A, Ilhan M, Cayo B. Frequency of vitamin D insufficiency in healthy children between 1 and 16 years of age in Turkey. Pediatr Int 2011;53:968-973.

4. Asner S, Ammann RA, Oszainh B, Beck-Popovic M, von der Weid NX. Obesity in long-term survivors of childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2008;51:118-122.

3. Shaw MP, Bath LE, Duff J, Kelnar CJ, Wallace WH. Obesity in leukemia survivors: the familial contribution. Pediatr Hematol Oncol 2000;17:231-237.

2. Mills JL, Fears TR, Robison LL, Nicholson HS, Sklar CA, Byrne J. Menarche in a cohort of 188 long-term survivors of acute lymphoblastic leukemia. J Pediatr 1997;131:598-602.

1. Chow EJ, Friedman DL, Yasui Y, Whitton JA, Stovall M, Robison LL, Sklar CA. Timing of menarche among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer 2008;50:854-858.